Superworth

Tonix Pharmaceuticals price to book ratio TNXP

Market value divided by the book value of the company's net assets, since 2012.

Today, Oct 23, 2026
0.4×
10-year median
1.1×
Against its 10-year history
14th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.0× to 33.5×
Peer median
1.6×

Tonix Pharmaceuticals' price to book ratio is 0.4× as of Oct 23, 2026.

That is below its ten-year median of 1.1×, lower than on 86% of days in the last ten years.

Over that time it ranged from 0.0× in Aug 2024 to 33.5× in Mar 2021.

The median for 10 large drugmakers of a similar size is 1.6×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.4×0.4×1.1×
20250.8×0.2×2.7×
20240.9×0.0×1.5×
20230.1×0.1×2.0×
20220.6×0.5×4.6×
20214.9×4.9×33.5×
202010.6×0.4×24.2×
20191.1×0.6×3.8×
20180.6×0.6×2.3×
20171.0×0.6×1.6×
20160.7×0.4×1.2×
20151.4×0.7×1.7×
20140.8×0.5×4.6×
20132.5×1.0×4.4×
20128.7×8.1×11.1×

Against its peers

Companies in Drug Manufacturers - General nearest Tonix Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
TNXPTonix Pharmaceuticals0.4×
LFVNLifevantage2.2×
SPROSpero Therapeutics1.5×
ATNMActinium Pharmaceuticals1.6×
NATRNatures Sunshine Products1.3×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
Peer median1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Tonix Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.